SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BINX: Incredible Product -- Ignore unavailable to you. Want to Upgrade?

To: Howard who wrote (87)1/3/1998 2:53:00 PM
From: James Baker  Read Replies (1) | Respond to of 103
 
Howard,
Are you still with us? I assume that you saw H&Q lowered their estimates on BINX stating that they were overly optimistic and just dropped back into the consensus pack for cover. The Arrow was mentioned as not continuing to take off as expected. Have you seen any change in the acceptance of the Arrow in Ortho or any competition in the amrket that we need to be aware of?
Thanks,
Jim



To: Howard who wrote (87)2/22/1998 4:21:00 PM
From: JerryR  Read Replies (2) | Respond to of 103
 
Howard, (or anyone else): post #2 indicated you thought less than 5% of the surgeries would involve the arrow. Is that still the case? Also, in what cases can the arrow be used and when is it not appropriate to use? It is my understanding that much of the meniscus doesn't repair because of lack of blood supply. TIA, Jerry


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News